PSMA-BCH
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H556251

CAS#: 1703768-73-3

Description: PSMA-BCH also known as NOTA-PSMA, is a PSMA- NOTA-conjugated precursor. 68Ga-PSMA-BCH can be used for prostate cancer imaging. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer. 64Cu-PSMA-BCH is a new radiotracer for delayed PET imaging of prostate cancer. 64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry.


Chemical Structure

img
PSMA-BCH
CAS# 1703768-73-3

Theoretical Analysis

Hodoodo Cat#: H556251
Name: PSMA-BCH
CAS#: 1703768-73-3
Chemical Formula: C45H64N8O14
Exact Mass: 940.45
Molecular Weight: 941.049
Elemental Analysis: C, 57.44; H, 6.86; N, 11.91; O, 23.80

Price and Availability

Size Price Availability Quantity
10mg USD 1650 2 Weeks
200mg USD 4950 2 Weeks
50mg USD 5250 2 Weeks
25mg USD 6950 2 Weeks
Bulk inquiry

Synonym: PSMA-BCH; NOTA-PSMA;

IUPAC/Chemical Name: L-Lysine, N6-[N-[[trans-4-[[[2-[4,7-bis(carboxymethyl)octahydro-1H-1,4,7-triazonin-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-3-(2-naphthalenyl)-L-alanyl]-N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-

InChi Key: RNAPMUOYIJWPGN-FUFSVGPLSA-N

InChi Code: InChI=1S/C45H64N8O14/c54-37(26-51-17-19-52(27-39(57)58)21-22-53(20-18-51)28-40(59)60)47-25-29-8-12-32(13-9-29)41(61)48-36(24-30-10-11-31-5-1-2-6-33(31)23-30)42(62)46-16-4-3-7-34(43(63)64)49-45(67)50-35(44(65)66)14-15-38(55)56/h1-2,5-6,10-11,23,29,32,34-36H,3-4,7-9,12-22,24-28H2,(H,46,62)(H,47,54)(H,48,61)(H,55,56)(H,57,58)(H,59,60)(H,63,64)(H,65,66)(H2,49,50,67)/t29-,32-,34-,35-,36-/m0/s1

SMILES Code: O=C(O)[C@H](CCCCNC([C@H](CC1=CC=C2C=CC=CC2=C1)NC([C@H]3CC[C@H](CNC(CN4CCN(CC(O)=O)CCN(CC(O)=O)CC4)=O)CC3)=O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 941.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ren Y, Liu T, Liu C, Guo X, Wang F, Zhu H, Yang Z. An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2022 Apr 22;15(5):513. doi: 10.3390/ph15050513. PMID: 35631340; PMCID: PMC9143078.


2: Hu K, Li L, Huang Y, Ye S, Zhong J, Yan Q, Zhong Y, Fu L, Feng P, Li H. Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging. Pharmaceuticals (Basel). 2022 Mar 21;15(3):383. doi: 10.3390/ph15030383. PMID: 35337180; PMCID: PMC8949503.


3: Liu T, Liu C, Zhang Z, Zhang N, Guo X, Xia L, Jiang J, Xie Q, Yan K, Rowe SP, Zhu H, Yang Z. 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4508-4516. doi: 10.1007/s00259-021-05426-9. Epub 2021 Jun 25. PMID: 34170361.


4: Liu T, Liu C, Xu X, Liu F, Guo X, Li N, Wang X, Yang J, Yang X, Zhu H, Yang Z. Preclinical Evaluation and Pilot Clinical Study of Al18F-PSMA-BCH for Prostate Cancer PET Imaging. J Nucl Med. 2019 Sep;60(9):1284-1292. doi: 10.2967/jnumed.118.221671. Epub 2019 Feb 22. PMID: 30796170.


5: Liu T, Liu C, Liu F, Xu X, Guo X, Xia L, Zhu H, Yang Z. Synthesis and preclinical evaluation of 68Ga-PSMA-BCH for prostate cancer imaging. Bioorg Med Chem Lett. 2019 Apr 1;29(7):933-937. doi: 10.1016/j.bmcl.2019.01.013. Epub 2019 Jan 17. PMID: 30745258.